MaaT bags €18M to test microbiome modulators in cancer patients

MaaT Pharma has raised an €18 million ($20 million) series B round. The financing equips MaaT to wrap up a phase 2 trial of its lead microbiome therapy in graft-versus-host disease (GVHD) while expanding into solid tumors.